NCT01208155

Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets

An Open-label, Randomized, Four-way Crossover Study in Healthy Male Subjects to Assess the Relative Bioavailability of 4 Different Fostamatinib Tablets

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Study in healthy males to assess bioavailability of 4 different fostamatinib tablets

Conditions

• Bioavailability
• Pharmacokinetics

Interventions

Type	Name	Description
DRUG	Fostamatinib	Oral tablets, 50 mg x 2, single dose
DRUG	Fostamatinib	Oral tablets, 100 mg Batch 1, single dose
DRUG	Fostamatinib	Oral tablets, 100 mg Batch 2, single dose
DRUG	Fostamatinib	Oral tablets, 100 mg Batch 3, single dose

Timeline

• Start date: 2010-09-01
• Primary completion: 2010-11-01
• Completion: 2010-11-01
• First posted: 2010-09-23
• Last updated: 2010-12-08

Locations

1 site across 1 country: United States